astrazeneca glp 1 AZ to terminate once-daily cotadutide program to focus on weekly GLP-1RA co-agonist AstraZeneca's ECC5004: Pioneering oral GLP-1RA

Gastric distention by balloon and test-meal intake in obese and lean subjects

We estimate that roughly half of people affected by obesity in the US will be eligible to benefit from GLP-1s overall, around 50 million people

Further mechanistic studies were initiated investigating whether SAR425899 targets the GCGR including effects on energy expenditure and amino acid patterns

J Ren Nutr

The medication has demonstrated significant weight loss in clinical trials, with participants losing an average of 12-15% of their body weight over 68 weeks in the STEP clinical trial programme

Those with a BMI of 35 or over may be eligible for bariatric surgery covered by Medicare